What is Stifel's price target for BDTX?

Stifel's latest stated price target for Black Diamond Therapeutics Inc. (BDTX) is $8, from its action on Oct 16, 2025.

What is Stifel's rating on BDTX?

Stifel rates BDTX Buy, a bullish rating, as of Oct 16, 2025.

When did Stifel last change its view on BDTX?

On Oct 16, 2025, Stifel resumes coverage at Buy, price target $8.

Stifel BDTX price target and rating history

Black Diamond Therapeutics Inc. (BDTX) · Health Care

Stifel rates Black Diamond Therapeutics Inc. (BDTX) Buy with a $8 price target, as of its latest action on Oct 16, 2025. It has published 3 rating actions on BDTX since September 2021, including 1 upgrade and 0 downgrades.

Current rating: Buy
Price target: $8
Median target, all firms: Too few
Actions on BDTX: 3

Stifel price target on BDTX

Stifel price target on BDTX, each point a stated target, September 2021 to October 2025. Targets before June 2023 (divided by 5) are adjusted for a stock split, going by the prior target Stifel restated.

Every Stifel rating on BDTX

Oct 16, 2025
ResumeStifel resumes coverage at Buy, price target $8
Jun 30, 2023
UpgradeStifel upgrades to Buy from Hold, price target $2 to $10
Sep 30, 2021
InitiateStifel starts coverage at Hold, price target $10

How other firms rate BDTX

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Guggenheim	Neutral		Dec 3, 2025
Piper Sandler	Overweight	$9	Nov 18, 2025

Questions about Stifel and BDTX

What is Stifel's price target for BDTX?: Stifel's latest stated price target for Black Diamond Therapeutics Inc. (BDTX) is $8, from its action on Oct 16, 2025.
What is Stifel's rating on BDTX?: Stifel rates BDTX Buy, a bullish rating, as of Oct 16, 2025.
When did Stifel last change its view on BDTX?: On Oct 16, 2025, Stifel resumes coverage at Buy, price target $8.

All Stifel ratings BDTX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.